Arsenal Capital Partners Buys Certara | GenomeWeb

NEW YORK (GenomeWeb News) – Private equity firm Arsenal Capital Partners today announced it has bought Certara, a provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.

Arsenal bought Certara from Vector Capital, which backed Jim Hopkins in forming Certara in 2007. Hopkins is now Certara's CEO.

The financial details of the acquisition were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.